Genetic influences on response to asthma pharmacotherapy

Expert Review of Clinical Pharmacology

Volumn 1, Issue 5, 2008, Pages 649-660

  Lima, John J ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Asthma; Genes; Personalized medicine; Polymorphisms; Response heterogeneity

Indexed keywords

ANTIASTHMATIC AGENT; ARGININE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE; FORMOTEROL FUMARATE; GENE PRODUCT; GLYCINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; PRANLUKAST; PROTEIN ABCC1; PROTEIN ACP; PROTEIN ALOX5; PROTEIN CRHR1; PROTEIN FCER2; PROTEIN LTA4H; PROTEIN LTC4S; PROTEIN SLCO2B1; PROTEIN TBX21; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PHARMACOGENETICS; PHARMACOLOGICAL BLOCKING; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM;

EID: 55649117947     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.5.649     Document Type: Review

References (89)

1. Becker KG. The common variants/multiple disease hypothesis of common complex genetic disorders. Med. Hypotheses 62 (2), 309-317 (2004).
2. Sly RM. Decreases in Hispanic and non-Hispanic asthma mortality. Ann. Allergy Asthma Immunol. 96(1), 76-79 (2006).
3. Expert Panel Report 3 (EPR-3). Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J. Allergy Clin. Immunol. 120(5 Suppl.), S94-S138 (2007).
4. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56(4), 1054-1070 (2000).
5. Lessells CM, Boag P. Unrepeatable repeatabilities a common mistake. Auk 104, 116-121 (1987).
6. Lima JJ. Pharmacogenetics: how will this change asthma management? In: Clinical Asthma. Castro M, Kraft M (Eds). Mosby Elsevier, PA, USA 229-237 (2008).
7. Lohse MJ. Molecular mechanisms of membrane receptor desensitization. Biochim. Biophys. Acta 1179(2), 171-188 (1993).
8. Barnes PJ. b-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 152(3), 838-860 (1995).
9. Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir. Res. 4(1), 2 (2003).
10. Hakonarson H, Grunstein MM. Regulation of second messengers associated with airway smooth muscle contraction and relaxation. Am. J. Respir. Crit. Care Med. 158(5 Pt 3), S115-S122 (1998).
11. Blake KV, Madabushi R, Derendorf H, Lima JJ. Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. Chest DOI: 10.1378 (2008) (Epub ahead of print).
12. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA 97(19), 10483-10488 (2000).
13. 2 in a multiethnic asthma case-control study. Am. J. Respir. Crit. Care Med. 174(10), 1101-1109 (2006).
14. 2 adrenergic receptor polymorphism associates with markers of asthma severity in African Americans. J. Asthma 43(3), 185-191 (2006).
15. 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects. Allergol. Int. 55(2), 191-198 (2006).
16. 2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 156(4 Pt 2), S156-S162 (1997).
17. Lima JJ, Mohamed M, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. 65, 519-525 (1999).
18. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100(12), 3184-3188 (1997).
19. 2-adrenoceptor haplotype in patients with asthma. Am. J. Respir. Crit. Care Med. 172(6), 700-703 (2005).
20. 2-adrenergic receptor ADRB2 haplotype tagging single nucleotide polymorphisms (htSNPs). Am. J. Respir. Crit. Care Med. 177, A568 (2008) (Abstract).
21. Litonjua AA, Tantisira K, Lasky-Su et al. Genome-wide association analysis of bronochodilator response in asthma. Am. J. Respir. Crit. Care Med. 177, A776 (2008) (Abstract).
22. 2-agonists on airway inflammation in asthmatic patients. Respir. Med. 94(Suppl. F), S22-S25 (2000).
23. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285(20), 2583-2593 (2001).
24. Speizer FE, Dolt R, Heaf P, Strang LB. Investigation into use of drugs preceding death from asthma. BMJ 1 (5588), 339-343 (1968).
25. Stolley PD. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am. Rev. Respir. Dis. 105(6), 883-890 (1972).
26. Crane J, Pearce N, Flatt A et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1983: case-control study. Lancet 1(8644), 917-922 (1989).
27. Grainger J, Woodman K, Pearce N et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1987: a further case-control study [see comments]. Thorax 46(2), 105-111 (1991).
28. Sears MR, Taylor DR, Print CG et al. Regular inhaled β-agonist treatment in bronchial asthma [see comments]. Lancet 336(8728), 1391-1396 (1990).
29. Taylor DR, Sears MR, Herbison GP et al. Regular inhaled β agonist in asthma: effects on exacerbations and lung function [see comments]. Thorax 48(2), 134-138 (1993).
30. Drazen JM, Israel E, Boushey HA et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N. Engl. J. Med. 335(12), 841-847 (1996).
31. Dennis SM, Sharp SJ, Vickers MR et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 355(9216), 1675-1679 (2000).
32. Taylor DR, Town GI, Herbison GP et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 53(9), 744-752 (1998).
33. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 158(3), 924-930 (1998).
34. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann. Intern. Med. 144(12), 904-912 (2006).
35. Lemanske RF Jr, Sorkness CA, Mauger EA et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285(20), 2594-2603 (2001).
36. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129(1), 15-26 (2006).
37. 2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst. Rev. 1, CD001385 (2007).
38. 2-agonists for asthma: the pediatric perspective. Clin. Rev. Allergy Immunol. 31 (2-3), 209-218 (2006).
39. Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 130(6), 1733-1743 (2006).
40. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am. J. Respir. Crit. Care Med. 156(3 Pt 1), 688-695 (1997).
41. Kelly HW. Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines. J. Allergy Clin. Immunol. 120(5), 989-994 (2007).
42. 2-agonists in management of childhood asthma: a critical review of the literature. Pediatr. Pulmonol. 29(3), 221-234 (2000).
43. 2 agonists on exacerbation rates of asthma in children. Pediatr. Pulmonol. 36(5), 391-398 (2003).
44. 2-agonist therapy in asthma. Eur. Respir. J. 11(3), 589-593 (1998).
45. 2 adrenoceptor polymorphism. Thorax 55(9), 762-767 (2000).
46. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 162(1), 75-80 (2000).
47. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364(9444), 1505-1512 (2004).
48. 2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br. J. Clin. Pharmacol. 57(1), 68-75 (2004).
49. 2-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 173 (5), 519-526 (2006).
50. Martinez FD. Safety of long-acting β-agonists - an urgent need to clear the air. N. Engl. J. Med. 353 (25), 2637-2639 (2005).
51. 2-adrenergic receptor genotype in subjects with persistent asthma. J. Allergy Clin. Immunol. 118(4), 809-816 (2006).
52. 2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370 (9605), 2118-2125 (2007).
53. 2 agonists. Lancet 370(9605), 2075-2076 (2007).
54. 2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61(11), 940-944 (2006).
55. Stewart L, Szefler S, Corar R. Corticosteroids. In: Cinical Asthma. Castro M, Kraft M (Eds). Mosby Elsevier Inc, PA, USA 251-262 (2008).
56. Malmstrom K, Rodriguez-Gomez G, Guerra J et al. Oral montelukast, inhaled bedomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann. Intern. Med. 130(6), 487-495 (1999).
57. Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. (2004).
58. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115(2), 233-242 (2005).
59. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyi cyclase type 9 in asthma: interaction between β-agonist and corticosteroid pathways. Hum. Mol. Genet. 14(12), 1671-1677 (2005).
60. Tantisira KG, Hwang ES, Raby BA et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc. Natl Acad. Sci. USA 101(52), 18099-18104 (2004).
61. Tantisira KG, Silverman ES, Mariani TJ et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J. Allergy Clin. Immunol. 120(6), 1285-1291 (2007).
62. Peters-Golden M, Henderson WR Jr. Leukotrienes. N. Engl. J. Med. 357(18), 1841-1854 (2007).
63. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58(3), 375-388 (2006).
64. NAEPP2002. National Institutes of Health: National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics 2002. J. Allergy Clin. Immunol. 110, S142-S219 (2002).
65. O'Byrne P, Bateman ED, Busse W et al. Pocket Guide for Asthma Management and Prevention. NIH Publication No. 02-3659 (2005) (Pamphlet).
66. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am. J. Respir. Crit. Care Med. 150(3), 618-623 (1994).
67. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J. Allergy Clin. Immunol. 98(5 Pt 1), 859-871 (1996).
68. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 126(3), 177-183 (1997).
69. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 158(11), 1213-1220 (1998).
70. DuBuske LM, Grossman J, Dube LM, Swanson LJ, Lancaster JF. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. Am. J. Manag. Care 3(4), 633-640 (1997).
71. Israel E, Chervinsky PS, Friedman B et al. Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol. 110(6), 847-854 (2002).
72. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 324(7353), 1545 (2002).
73. 2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. 1, CD003137 (2005).
74. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am. J. Respir. Crit. Care Med. 175(3), 235-242 (2007).
75. Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22(2), 168-170 (1999).
76. Sampson AP, Siddiqui S, Buchanan D et al. Variant LTC (4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55(Suppl. 2), S28-S31 (2000).
77. Asano K, Shiomi T, Hasegawa N et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12(7), 565-570 (2002).
78. Whelan GJ, Blake K, Kissoon N et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr. Pulmanol. 36(5), 413-420 (2003).
79. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 173(4), 379-385 (2006).
80. Klotsman M, York TP, Pillai SG et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet. Genomics 17(3), 189-196 (2007).
81. Telleria JJ, Blanco-Quiros A, Varillas D et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir. Med. 102(6), 857-861 (2008).
82. Mougey EB, Feng H, Castro M, Irvin C, Lima J. Transporter mediated absorption of montelukast in a CACO-2 model system. Clin. Pharmacol. Ther. 83, S67 (2008) (Abstract).
83. Mougey EB, Feng H, Irvin C, Lima J. Montelukast plasma concentration associates with a common SNP on SLCO2B1. Clin. Pharmacol. Ther. 83, S67 (2008) (Abstract).
84. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 114(4), 998-1007 (1998).
85. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343 (8904), 1006-1008 (1994).
86. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N. Engl. J. Med. 337(20), 1412-1418 (1997).
87. Obase Y, Shimoda T, Kawano T et al. Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin. Pharmacol. Ther. 73(5), 468-474 (2003).
88. Yoon Y, Park HD, Park KU, Kim JQ, Chang YS, Song J. Associations between CYP2E1 promoter polymorphisms and plasma 1,3 -dimethyluric acid/ theophylline ratios. Eur. J. Clin. Pharmacol. 62(8), 627-631 (2006).
89. Takata K, Saruwatari J, Nakada N et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur. J. Clin. Pharmacol. 62(1), 23-28 (2006).